Metachronous metastasis of renal cell carcinoma to the urinary bladder: a case report (original) (raw)
Related papers
Metastasis of Renal Cell Carcinoma to the Urinary Bladder: Case Report
Zenodo (CERN European Organization for Nuclear Research), 2022
Renal cell carcinoma (RCC) is the most common malignant type among kidney tumors, with a rate of 90% in adults. Distant metastasis is seen in 30% of patients with Renal Cell Carcinoma at the time of diagnosis. In this study, we aimed to present two very rare cases of bladder metastases. Case 1; A 65-year-old male patient with nodular thickening and mass in the bladder wall around the right ureteral orifice. Case 2; The patient, who had undergone nephrectomy operation due to a mass in the left kidney, was hospitalized with the complaint of hematuria and a mass in the bladder was detected in the examination.Although metastasis of Renal Cell Carcinoma to the bladder is not common, it should be kept in mind in routine control examinations and investigated for metastasis.
World Journal of Surgical Oncology, 2016
Background: Renal cell carcinoma developing metastases in the bladder is rare. Bladder metastasis due to a papillary type of renal cell carcinoma is rarer. Such metastases could be synchronous or metachronous. Case presentation: Here we present a 55-year-old female patient with haematuria who underwent left nephroureterectomy for a suspected urothelial tumour. Histopathology revealed it to be a type 2 papillary renal cell carcinoma. Eighteen months later, she developed metachronous bladder metastasis of the papillary renal cell carcinoma which was treated with total cystectomy. Currently, she is on interferon therapy. Conclusions: These bladder metastases from renal cell carcinoma could be due to drop metastases, lymphatic spread or haematogenous spread. The exact mechanism in a given case appears to be unpredictable.
Metastatic Renal cell Carcinoma (Clear Cell Carcinoma) to the Urinary Bladder
Metastatic renal cell carcinomas to the urinary bladder (MRCCTUB) are rarely encountered. Literature review on MRCCTUB was done by using various internet data bases to identify literature on MRCCTUB using the following search words: renal cell carcinoma metastatic to bladder; clear cell carcinoma metastatic to bladder. The review revealed that less than 100 cases of MRCCTUB have been reported in the English literature. MRCCTUBs may be synchronous or metachronous. MRCCTUBs may present with haematuria or lower urinary tract symptoms. Radiological imaging reveals a bladder mass. Cystoscopy reveals a non-papillary, solid, polypoid, pedunculated mass which may be yellowish. Metastatic renal cell carcinoma of the urinary bladder exhibits the following features: Delicate fibro-vascular stroma with abundant sinusoidal vessels, polygonal cells with abundant clear cytoplasm and nuclei. They may resemble urothelial carcinoma with clear cell features. MRCCTUBs on immunohistochemistry stain: (a) Positively with CAM 5.2, vimentin, Leu-M1 (CD15) (b) negatively with CK7, CK20, 34betaE12, CEA, S100, HMB45, chromogranin. The prognosis of MRCCTUs, have been generally poor and may depend upon whether they are solitary metastases or associated with metastases to other organs. MRCCTUs have on a number of occasions been confined to the bladder mucosa and these have been treated by trans-urethral resection. There is anecdotal information to suggest that intravesical BCG may help prevent local bladder recurrence. Systemic therapies have been used to treat disseminated disease with on the whole poor outcome. There is no consensus of opinion regarding the best treatment option. MRCCTUs are rare and there is no consensus opinion regarding their treatment in relation to other disseminated metastases. There is need for all cases of MRCCTUs to be entered in a multi-centric trial. Urologists and Oncologists should report cases of MRCCTUs they encounter.
Rapid metachronous bladder metastasis of type 2 papillary renal cell carcinoma
Archive of Clinical Cases, 2023
Renal cell carcinoma (RCC) frequently spreads to distant organs like the lung, lymph nodes, bone, and liver. However, there have been some reports of RCC bladder metastasis. We present a case of a 61-year-old man presented with total painless gross hematuria. The patient had a history of right radical nephrectomy for papillary (type 2) RCC, high-grade, pT3a with negative surgical margins. There was no evidence of metastases on 6-month surveillance CT. After one-year post-operation, at this current admission, the cystoscopy discovered a solid bladder mass away from the trigone in the right lateral bladder wall. The resected bladder mass was metastatic papillary RCC with PAX-8 positive but GATA-3 negative on immunostaining. A positron emission tomography scan confirmed multiple lung, liver, and osseous metastases. This case report can highlight the importance of having bladder metastasis in RCC mind, although rare, and may necessitate the surveillance measures like urine analysis at more frequent interval and CT Urography instead of regular CT to detect the RCC metastatic bladder cancer at early stage.
Solitary ureteral metastases of renal cell carcinoma
Urology, 2006
Metachronous presentation of metastatic renal cell carcinoma (RCC) to the ureter is extremely rare. We report a solitary metachronous metastatic RCC in the contralateral ureter 14 months after right radical nephrectomy for Fuhrman grade 2 pT3a clear cell disease after the patient re-presented with gross hematuria. The proximal left ureteral lesion was excised followed by ileal-ureteral interposition. Pathologic examination confirmed metastatic RCC. To date, only 51 cases of metastatic RCC to the ureter have been reported, with only 6 occurring metachronously in the contralateral ureter. Also, we report the presence of focal extramedullary hematopoiesis occurring within this metastatic lesion. UROLOGY 68: 428.e5-428.e7, 2006.
A rare case of synchronous renal cell carcinoma of the bladder presenting with gross hematuria
Rare Tumors, 2013
A 57-year old man was referred to the Urology Department due to gross hematuria; abdominal ultrasound revealed an unspecific solid tumor of the left bladder wall. Ultrasound, transurethral resection of the bladder mass with subsequent histological analysis, thoracic and abdominal computed tomography-scan and brain magnetic resonance imaging were performed. He was diagnosed with a bladder metastasis of clear cell renal cell carcinoma (RCC) with concomitant bone, pulmonary, and cerebral metastatic disease of a primary RCC of the right kidney. Management: Transurethral resection of the bladder mass, cerebral and bone radiotherapy, removal of the primary tumor, targeted systemic therapy with mTOR followed by tyrosine kinase inhibition.
Urology Annals, 2016
Renal cell cancer (RCC) is known to produce metastasis to unusual sites both synchronously and metachronously several years after the primary treatment. We report a rare case of RCC with three different, sequential, and each time isolated rare site metastasis to ureteric stump, surgical site, and urinary bladder over a period of 6 years after radical nephrectomy. At each recurrence, metastasectomy was carried out and no systemic therapy was administered. Eleven years after radical nephrectomy and 5 years after last resection, the patient remains disease free. Multiple recurrences can occur in RCC and complete surgical resection results in disease free survival.
Solitary metastases from renal cell carcinoma: A review
Journal of Surgical Oncology, 1992
Nineteen patients with solitary metastatic lesions from renal cell carcinoma, 5 synchronous and 14 metachronous, were seen at the Tata Memorial Hospital over a 7 year period between 1981 and 1987. The mean metastatic interval for the metachronous lesions was 31.2 months. The commonest sites of metastases were bone, lung, and liver. The solitary nature of the metastasis was confirmed by appropriate investigations. All patients underwent nephrectomy for the primary kidney lesion. The metastatic lesions were treated with intent of cure. Only l patient with synchronous metastasis survived for 2 years and none survived 5 years while in the metachronous metastasis group, the estimated overall survival was 50% at 2 years and 25% at 5 years. The patients with a long metastasis-free interval were found to have a better survival. The patients with liver metastasis did poorly as compared to those with metastases at other sites. The stage of the disease also had a bearing on the survival.
2021
Patient: Female, 46-year-old Final Diagnosis: Metastasis of renal clear cell carcinoma Symptoms: Renal carcinoma Medication:— Clinical Procedure: — Specialty: Urology Objective: Unusual setting of medical care Background: One-third of renal cell carcinoma cases present with an initial metastasis to various organs, emphasizing the tumor’s unpredictable behavior. Prognosis is poor once metastasis is discovered. Multiple-organ involvement with metastatic lesions has a particularly dismal survival rate. Surgical resection alone of metastatic masses can extend patient survival with reasonable quality of life. Case Report: Here, we present the case of a healthy 46-year-old woman who initially presented with an incidental localized clear cell renal cell carcinoma. During the follow-up period, she presented with sequential asynchronous metastasis to the pancreas, thyroid, skin, contralateral kidney, and lung. She has no family history of malignancy. Her physical examination and laboratory i...